First Large-scale U.S. Study on Hydroxychloroquine COVID-19 Prophylaxis Begins in Detroit. #COVID19 #coronavirus #SARScov2

April 10, 2020 — Enrollment began April 9 at Henry Ford Hospital for the first large-scale study in the United States of the effectiveness of the anti-malarial drug hydroxychloroquinein in preventing COVID-19 in healthcare workers and first responders who volunteer to participate.

In less than a day the study already had more than 1,000 volunteers enroll. Interim results are expected in 30 days and final results of this lighting-speed trial will be available by this summer.
The American College of Cardiology (ACC) released a list of the latest practice-changing presentations at the ACC.20 annual meeting March 28-30, 2020, in Chicago. This includes five late-breaking clinical trial (LBCT) sessions and three featured clinical research sessions. There also are two LBCT deep-dive sessions where the experts will break down the hottest trials and attendees can find out what the impact might be on the practice of cardiology and patients.

Here is the list of American College of Cardiology (ACC) practice-changing late-breaking study presentations at the ACC.20 annual meeting March 28-30, 2020. The meeting was supposed to take place in Chicago, but due to the spread of the novel coronavirus (COVID-19, SARS-CoV-2) pandemic, the in-person event was cancelled and the ACC organized a scaled back virtual conference within 3 weeks. The virtual presentations include five late-breaking clinical trial (LBCT) sessions and three featured clinical research sessions. 
Abbott announced its TriClip Transcatheter Tricuspid Valve Repair (TTVR) System has received European CE mark clearance as a non-surgical treatment for people with a tricuspid valve regurgitation (TR). 

April 9, 2020 — Abbott announced its TriClip Transcatheter Tricuspid Valve Repair (TTVR) System has received European CE mark clearance as a non-surgical treatment for people with a tricuspid valve regurgitation (TR). 

April 8, 2020 — There has been debate in the past month or so during the novel coronavirus (COVID-19) pandemic whether the renin-angiotensin-aldosterone system (RAAS) inhibitors, such as angiotensin-converting–enzyme (ACE) inhibitors and angiotensin-receptor blockers (ARBs), should be stopped in COVID-19 patients. An article in the New England Journal of Medicine (NEJM) suggests these medications provide known benefits to patients who need them, while potential harms remain unproven.[1]

April 8, 2020 — Research to help increase awareness of the cardiovascular manifestations of COVID-19 disease and the adverse impact of cardiovascular involvement on prognosis was published in Circulation April 3, the journal of the American Heart Association (AHA).

Caution Recommended in use of COVID-19 Therapy Using Hydroxychloroquine and Azithromycin in Cardiovascular Disease Patients

April 8, 2020 – The scientific community is learning more about the impact and interaction of cardiovascular diseases with novel coronavirus (COVID-19, SARS-CoV-2), including the impact of drug therapies being used and their negative cardiovascular impact.

April 7, 2020 — Boston Scientific Corp. is recalling its Imager II 5 French angiographic catheters, because there is a potential for the catheter tip to become detached during a procedure or during procedure preparation. 

April 7, 2020 — Baylis Medical, a Canadian-based medical device company specializing in cardiology and spine, announced it is partnering with Ventilators for Canadians, a consortium of Canadian manufacturers, to manufacture ventilators for hospitals across Canada. This effort will aid the response to the novel coronavirus (COVID-19, SARS-CoV-2) pandemic.

An ECMO cannula being inserted into a cardiovascular patient in need of mechanical oxygenation and hemodynamic support in December 2019. The FDA just made a temporary approval to use ECMO support in COVID-19 patients during the pandemic emergency. #COVID19 #SARScov2 #coronavirus

April 7, 2020 — The U.S. Food and Drug Administration (FDA) has issued guidance to provide a policy to help expand the availability of devices used in extracorporeal membrane oxygenation (ECMO) therapy to address the novel coronavirus (COVID-19, SARS-CoV-2) public health emergency.
COVID-19 by far was the largest driver of DAIC website traffic in March 2020. Clinicians quickly wanted to access information of the disease and its relation to cardiology as the virus rapidly spread across the United States and Europe within just the four weeks of March. #COVID19 #coronavirus #SARScov2

April 6, 2020 — Here is the list of the most popular content on the Diagnostic and Interventional Cardiology (DAIC) magazine website from the month of March 2020. This is based on the website’s 296,206 pageviews for the month. Anything related to novel coronavirus (COVID-19) ranked at the top of this list this past month, helping drive near-record traffic numbers for the website:
Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now